首页> 外文会议>Annual International Vicenza Course on Hemodialysis >Noninwasiwe Wolume Assessment in the Emergencf Department; A Look at B-Type Natriuretic Peptide and Bioimpedance Wector Anaif sis
【24h】

Noninwasiwe Wolume Assessment in the Emergencf Department; A Look at B-Type Natriuretic Peptide and Bioimpedance Wector Anaif sis

机译:突发行业部的非瓦斯韦威评估;看B型利钠肽和生物阻抗WPORE ANAIF SIS

获取原文

摘要

B-type natriuretic peptide (BNP) and bioimpedance vector analysis (BIVA) are potential methods of assessing fluid status in patients. Their speed and ease of implementation allows them to be used at the point of care. Currently, BNP is pivotal in the diagnosis and prognosis of heart failure, and is starting to be implemented in other diseases (e.g. acute coronary syndrome and end-stage renal disease). Although it can be elevated from volume-overload-induced cardiac stress, when assessing volume this method is ultimately unreliable since it lacks adequate specificity and accuracy. Alternatively, BIVA is accurate and sensitive in the detection of fluid status, but cannot be used to tell the etiology of the volume aberration. Despite being relatively new, BIVA is becoming recognized as a superior method to assess volume.
机译:B型Natriuretic肽(BNP)和生物阻抗载体分析(BIVA)是评估患者流体状态的潜在方法。它们的速度和易于实现允许它们在护理点使用。目前,BNP在心力衰竭的诊断和预后枢转,并开始在其他疾病中实施(例如急性冠状动脉综合征和末期肾病)。虽然当评估体积时,它可以从体积过载引起的心脏压力升高,但是由于它缺乏足够的特异性和准确性,因此该方法最终是不可靠的。或者,在检测流体状态的检测中,BIVA是准确和敏感的,但不能用于讲述体积像差的病因。尽管存在相对较新的,BIVA变得被认为是评估体积的卓越方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号